Table 2.

Study sample baseline^a characteristics, 1387 ALIVE participants with a study visit in 2015 and 2019.

		Total
		n = 1387
		n	%
Predisposing	Age, median (range)	53	(27–77)
	Female sex	459	33
	Black race	1119	81
Enabling	Annual income <$5000	959	69
	Disability	1105	80
	Insurance last 6 months	1349	97
	Same provider in the last 2 years	775	56
Health behaviors (last 6 months)	Non-injection drug use only	193	14
	Injection drug use only	70	5
	Both injection and non-injection drug use	512	37
Healthcare utilization (last 6 months)	Emergency Department Visit	439	32
	Outpatient Clinic Visit	1046	75
	Medication for Opioid Use	734	53
	Disorderb
Need characteristics	HIV	413	30
	Diabetes	124	9
	Hypertension	826	60
	Renal Disease	110	8
	Arthritis	465	34
	Major Psychiatric	393	28
	Comorbidityc
	Anxiety/Depression	629	45
	Fibrosis (≥ 9.3 kPa)d	182	24
	Obstructive Airway Diseasee	152	23

^aFirst study visit in 2015–2019 represents the baseline visit.

^bMethadone, Buprenorphine, or Naltrexone.

^cBipolar or Schizophrenia.

^dFibroscan available for only 753 participants at first visit.

^eFEV/FCV available for only 658 participants at first visit.